The number of shares and votes in Nanologica AB has changed during the month of March as a result of the completion of the previously announced rights issue with preferential rights for existing shareholders.

As previously communicated, on 30 January 2024, Nanologica's board of directors resolved on a fully guaranteed rights issue of approximately MSEK 54.2 with preferential rights for existing shareholders, in order to finance intensified investments in preparative chromatography. On 15 March, Nanologica announced that the rights issue had been fully subscribed and that Nanologica through the rights issue, after transaction costs, had received approximately MSEK 40 in cash and cash equivalents in addition to loans corresponding to approximately MSEK 6.2 being offset against shares in the issue.
 
The rights issue has resulted in an increase in the number of shares in Nanologica of 8,032,476 shares during the month of March, from 36,146,142 to 44,178,618 shares. The Extraordinary General Meeting on 22 February 2024 resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue. The effect of this decision is that the company's share capital will not increase in connection with the registration of the rights issue but will continue to amount to approximately SEK 14,820,923.
 
As of 28 March 2024, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 44,178,618.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that provides consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-03-28 12:00 CET.

Attachments
Change of Number of Shares and Votes in Nanologica AB (publ)

© Modular Finance, source Nordic Press Releases